MacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - A class-action lawsuit has been filed against MacroGenics, alleging that the company misled investors regarding the safety and effectiveness of its experimental cancer drug, vobra duo, particularly in relation to data from the Phase 2 TAMARACK clinical trial [3]. Group 1: Lawsuit Details - The class-action lawsuit represents investors who purchased MacroGenics securities between March 7, 2024, and May 9, 2024 [1]. - Investors have until September 24, 2024, to file a lead plaintiff motion [1]. - The lawsuit was filed in the Southern District of New York [3]. Group 2: Drug Performance and Market Reaction - Prior to the ASCO meeting in March 2024, MacroGenics promoted vobra duo as having promising results for patients with metastatic castration-resistant prostate cancer (mCRPC) [4]. - On April 3, 2024, interim data from the TAMARACK study indicated that reducing the dose and frequency of vobra duo improved safety and tolerability, resulting in a share price increase of $4.11, or approximately 30%, on April 4, 2024 [5]. - However, on May 10, 2024, the company reported five patient deaths in the study, leading to a significant share price drop of $11.36, or roughly 77%, on the same day, which prompted multiple analyst downgrades [6].